Screener
Serina Therapeutics SER Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue$125.0KIn line
EPS-$0.31Beat by $0.03
Revenue estimate$125.0K
EPS estimate-$0.34
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252's potential as a differentiated treatment option for patients with advanced Parkinson's disease to improve the significant challenge of consistent symptom control.”
Next report
Date not yet announcedVersus estimates
Revenue
Q3 2026$125.0KIn line
Q2 2025$130.0KDiluted EPS
FAQ
- When did Serina Therapeutics report Q3 2026 earnings?
- Serina Therapeutics (SER) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Serina Therapeutics's Q3 2026 revenue and EPS?
- Serina Therapeutics reported revenue of $125.0K and eps of $-0.31 for Q3 2026.
- Did Serina Therapeutics beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $125.0K by -. EPS beat the consensus estimate of $-0.34 by $0.03.
- How did Serina Therapeutics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 31.1% from $-0.45.
- Where can I find Serina Therapeutics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001708599-26-000069) and the 10-Q periodic report (0001708599-26-000068) directly on SEC EDGAR. The filing index links above go to sec.gov.
